WHO —Dr. Robert E. W. Hancockchief operating officer and Rudy MazzocchiCEO
What — a free online webinar on the Company’s strategic importance, recent developments and revenue plans
Or – Zoom webinar, registration details below
When — Thursday, March 3, 2022, at 1 p.m. EST
Why — to give investors the opportunity to ask questions and get answers about the strategic importance of Asep Inc. in the medical field
dr. Robert E. W. Hancockchief operating officer
Dr. Hancock is a leading microbiologist in Canada who researched and taught University of British Columbia for nearly 40 years. His main interest is in designing new therapeutic strategies to treat infections and inflammation in light of growing antibiotic resistance, coupled with a dearth of new antibiotic discoveries. His research interests include cationic host defense peptides as novel antimicrobials, anti-biofilm agents, anti-inflammatory agents and modulators of innate immunity. He has published over 800 articles and reviews, has over 120,000 citations, an h-index of 174, and 72 issued patents. Awards and accolades include the Prix Galien (the highest honor for pharmaceutical research and innovation in Canada), the Killam Prize (Canada Council for the Arts prize for health research), the Researcher of the Year CIHR Michael Smith and the ICAAC Aventis Antimicrobial Research Award (the world’s most prestigious award for antimicrobial research). In 2001, he was inducted as an Officer of the Order of Canada.
Rudy A. Mazzocchi has over 30 years of experience in senior management, technology and intellectual property development and financing (institutional, venture, private and public) in the medical technology, biotechnology and pharmaceutical industries. biopharmacy. As the founder of more than a dozen healthcare companies, he has developed and commercialized several technologies ranging from diagnostics to implantable medical devices, requiring clinical validation and rigorous regulatory reviews, including regulatory clearance. FDA, CE mark and international regulatory approvals. As interim President/CEO of AGENTIX Biopharma Corp., he is simultaneously Co-Founder/Vice President of the BioMedX Group, Executive Chairman of MY NEXT HEALTH and independent director of several private and public companies, in the start-up and growth phase. , and senior advisor to various international companies seeking global expansion and access to US public markets. Mazzocchi previously served as Executive Chairman of Establishment Labs (NASDAQ:ESTA) and Independent Director of Greatbatch/Integer Medical (NYSE:ITGR) and is the author of over 100 patents and a recipient of the Ernst & Young Entrepreneur of the Year award. the year for health care.
REGISTER TODAY FOR THIS IMPORTANT WEBINAR
ABOUT ASEP MEDICAL HOLDINGS INC.
Asep Inc. is dedicated to solving antibiotic failure by developing new solutions for significant unmet medical needs. The Company is a consolidation of two existing private companies (Sepset Biosciences Inc. and ABT Innovations Inc.). Sepset Inc. is in the advanced development of proprietary diagnostic tools for the early and rapid identification of severe sepsis. ABT Inc. is in the advanced development of broad-spectrum therapeutic agents to treat multidrug-resistant biofilm infections.
Sepset Biosciences Inc. is developing diagnostic technology that involves a patient’s gene expression signature that predicts severe sepsis, one of the important diseases leading to antibiotic failure since antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for almost 20% of all deaths on the planet. The SepsetEmergencies is a blood-based gene expression test that is simple to perform and results are obtained in approximately one hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in that it can diagnose severe sepsis within 1-2 hours of first clinical presentation (i.e. in the emergency room), while other diagnostics provide a diagnosis only after 24 to 36 hours. Asep Inc. believes this will enable physicians to make critical early decisions about appropriate treatments and reduce overall morbidity and mortality from sepsis. Current modeling also suggests the SepsetEmergencies the test could save $16 billion annually in the unnecessary use of antibiotics.
ABT Innovations Inc.’s peptide technology covers a wide range of therapeutic applications, including bacterial biofilm infections (medical device infections, chronic infections, lung, bladder, wound, dental, skin, otolaryngology, sinusitis, orthopaedics, etc.), anti-inflammatories, anti-infective immunomodulators and vaccine adjuvants. ABT Inc. is currently in preclinical development for two separate products.
SOURCEASEP Medical Holdings Inc.